{"id":7212,"date":"2021-01-05T10:02:17","date_gmt":"2021-01-05T09:02:17","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=7212"},"modified":"2021-02-01T10:02:15","modified_gmt":"2021-02-01T09:02:15","slug":"andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/","title":{"rendered":"Andera sells its Life Sciences’ portfolio company Arvelle Therapeutics"},"content":{"rendered":"

\"\"<\/p>\n

 <\/p>\n

Andera co-led the $207.5m Series A financing of Arvelle Therapeutics in February 2019 and joined the company\u2019s board of directors. With the Series A funds, Arvelle in-licensed European product rights to Cenobamate from SK BioPharmaceuticals, prepared regulatory submission for the drug candidate and established a European structure.<\/p>\n

Cenobamate is a small molecule with a unique dual complementary mechanism of action. It acts by positively modulating the \u03b3-aminobutyric acid (GABAA) ion channel and inhibiting voltage-gated sodium currents. Key study findings documented Cenobamate\u2019s clinical efficacy by showing a significant greater reduction in median seizure frequency and more patients achieving a 50% or greater reduction in seizure frequency compared to the placebo group (see press release link below<\/a>). Cenobamate is approved by the Food and Drug Administration (FDA) in the United States as an anti-seizure medication for the treatment of focal-onset epileptic seizures in adults.\u00a0In 2020 Arvelle filed for European approval of Cenobamate.<\/p>\n

This transaction is the second industrial sale from Andera Life Sciences BioDiscovery 5 fund portfolio, following the sale of Corvidia to NovoNordisk for $2.1Bn in the summer of 2020. It further adds to four public listings of BioDiscovery 5 companies (Axonics, Erytech, LogicBio and Nyxoah), and occurs still during the funds\u2019 investment period.<\/p>\n","protected":false},"excerpt":{"rendered":"

  Andera co-led the $207.5m Series A financing of Arvelle Therapeutics in February 2019 and joined the company\u2019s board of directors. With the Series A funds, Arvelle in-licensed European product rights to Cenobamate from SK BioPharmaceuticals, prepared regulatory submission for the drug candidate and established a European structure. Cenobamate is a small molecule with a…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-7212","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"\nAndera sells its Life Sciences' portfolio company Arvelle Therapeutics - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera sells its Life Sciences' portfolio company Arvelle Therapeutics - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"  Andera co-led the $207.5m Series A financing of Arvelle Therapeutics in February 2019 and joined the company\u2019s board of directors. With the Series A funds, Arvelle in-licensed European product rights to Cenobamate from SK BioPharmaceuticals, prepared regulatory submission for the drug candidate and established a European structure. Cenobamate is a small molecule with a...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T09:02:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-02-01T09:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera sells its Life Sciences’ portfolio company Arvelle Therapeutics\",\"datePublished\":\"2021-01-05T09:02:17+00:00\",\"dateModified\":\"2021-02-01T09:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/\"},\"wordCount\":210,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png\",\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/\",\"name\":\"Andera sells its Life Sciences' portfolio company Arvelle Therapeutics - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png\",\"datePublished\":\"2021-01-05T09:02:17+00:00\",\"dateModified\":\"2021-02-01T09:02:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#primaryimage\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera sells its Life Sciences’ portfolio company Arvelle Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera sells its Life Sciences' portfolio company Arvelle Therapeutics - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Andera sells its Life Sciences' portfolio company Arvelle Therapeutics - ANDERA PARTNERS","og_description":"  Andera co-led the $207.5m Series A financing of Arvelle Therapeutics in February 2019 and joined the company\u2019s board of directors. With the Series A funds, Arvelle in-licensed European product rights to Cenobamate from SK BioPharmaceuticals, prepared regulatory submission for the drug candidate and established a European structure. Cenobamate is a small molecule with a...","og_url":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2021-01-05T09:02:17+00:00","article_modified_time":"2021-02-01T09:02:15+00:00","og_image":[{"url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png","type":"","width":"","height":""}],"author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera sells its Life Sciences’ portfolio company Arvelle Therapeutics","datePublished":"2021-01-05T09:02:17+00:00","dateModified":"2021-02-01T09:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/"},"wordCount":210,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png","articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/","url":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/","name":"Andera sells its Life Sciences' portfolio company Arvelle Therapeutics - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png","datePublished":"2021-01-05T09:02:17+00:00","dateModified":"2021-02-01T09:02:15+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#primaryimage","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/b62e59a5-bf0b-44d3-aba4-ac167dc334bd.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-sells-its-life-sciences-portfolio-company-arvelle-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Andera sells its Life Sciences’ portfolio company Arvelle Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/7212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=7212"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/7212\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=7212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=7212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}